Please login to the form below

Not currently logged in
Email:
Password:

evacetrapib

This page shows the latest evacetrapib news and features for those working in and with pharma, biotech and healthcare.

CETP inhibitor class finally dies as Merck abandons anacetrapib

CETP inhibitor class finally dies as Merck abandons anacetrapib

The drug follows in the footsteps of other CETP inhibitors - including Pfizer's torcetrapib, Roche's dalcetrapib and Eli Lilly's evacetrapib - although those candidates all failed to show a benefit

Latest news

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Pharma deals in September 2015 Pharma deals in September 2015

    Whilst Roche and Pfizer failed to overcome efficacy and safety concerns regarding their candidates, Eli Lilly's (evacetrapib) and Merck's (anacetrapib), products are looking to raise HDL levels and these

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics